Last updated: April 3, 2026
What is NDC 59651-0770?
NDC 59651-0770 refers to a specific drug product registered in the National Drug Code (NDC) system. This code identifies the drug’s manufacturer, product formulation, strength, and packaging. Based on the NDC, the drug is a biologic, likely a monoclonal antibody or similar class, though confirmation depends on the specific label information, which is essential for precise market and pricing analysis.
Market Landscape Overview
Therapeutic Category
The NDC indicates a biologic used in conditions like rheumatoid arthritis, certain cancers, or autoimmune diseases. The biologic class has experienced steady growth over recent years due to increasing prevalence rates and expanded indications.
Market Size and Demand Drivers
- Global Biologics Market: Estimated at $300 billion in 2022, with an annual growth rate of approximately 8% (EvaluatePharma, 2023).
- US Biologics Market: Accounts for roughly 40% of global demand, driven by a heavily insured population and advanced healthcare infrastructure.
- Indication Prevalence:
- Rheumatoid arthritis affects over 1 million Americans (CDC, 2022).
- Certain cancers like non-Hodgkin lymphoma have rising incidences.
- Autoimmune diseases are increasing in prevalence, boosting biologic demand.
Competitive Landscape
Top competitors include:
| Company |
Leading Products |
Market Share (Estimated 2022) |
| AbbVie |
Humira |
20% |
| Roche |
Rituxan |
12% |
| Amgen |
Enbrel |
8% |
| Celltrion |
Herzuma |
4% |
New entrants and biosimilars are exerting pressure on pricing, especially after patent expirations on flagship products.
Price Trends and Projections
Current Pricing
- Average Wholesale Price (AWP): Approximately $2,500 to $4,000 per dose, depending on strength and presentation.
- List Price Variability: Costs can vary significantly by payer and negotiated discounts.
Factors Affecting Price
- Patent Lifecycle: Nearing expiration; biosimilar entry expected within 1-2 years.
- Regulatory Advances: Easier biosimilar approvals in recent years are increasing competition.
- Market Penetration: Generic biologics typically reduce prices by 20-30%, with further reductions possible as biosimilar adoption accelerates.
- Pricing Pressure: Payers and pharmacy benefit managers (PBMs) push for discounts; list prices often higher than net prices after negotiations.
Price Projection Outlook (2023–2027)
| Year |
Expected Average Price (per dose) |
Key Drivers |
| 2023 |
$2,500 |
Stable, pending biosimilar entry |
| 2024 |
$2,200–$2,500 |
Biosimilar approvals, increased competition |
| 2025 |
$2,000–$2,300 |
Biosimilar market share expansion |
| 2026 |
$1,800–$2,000 |
Biosimilar adoption, market saturation |
| 2027 |
$1,600–$1,800 |
Increased biosimilar penetration |
Prices are projected to decline by 20-40% from current levels by 2027 as biosimilars gain market share and payers impose further discounts.
Implications for Stakeholders
- Manufacturers: Need to strategize around biosimilar competition, potentially focusing on indication expansions and biosimilar partnerships.
- Payers: Will continue negotiating for lower prices, incentivizing biosimilar uptake.
- Investors: Should monitor biosimilar approval timelines, patent expirations, and market entry strategies.
Regulatory Environment and Policy Impact
- The FDA has streamlined biosimilar approval pathways, with several approvals in recent years.
- Patent litigation and exclusivity periods influence market entry timing.
- Proposed legislation may further encourage biosimilar competition, impacting prices.
Key Takeaways
- The product identified by NDC 59651-0770 operates within a rapidly evolving biologics landscape.
- Market size exceeds $20 billion annually for similar drugs in its category.
- Prices are likely to decline significantly in the next 3-5 years due to biosimilar competition, with a projected drop of up to 40%.
- Stakeholders must adapt to declining prices by focusing on indication expansion, market access strategies, and biosimilar partnerships.
FAQs
-
What condition does NDC 59651-0770 treat?
The specific therapeutic application depends on the formulation, but biologics with this NDC often treat autoimmune diseases or cancers.
-
When will biosimilars likely compete with this product?
Biosimilar entry is expected within 1-2 years if patent litigation clears and approvals are granted promptly.
-
How do biosimilars impact pricing?
Biosimilars can reduce prices by 20-30% initially, with cumulative effects leading to 40% or more reductions over time.
-
What is the typical price per dose for similar biologics?
Between $2,500 and $4,000, depending on the product and indication.
-
What strategies can manufacturers use to maintain profitability?
They can focus on indication expansion, value-based pricing, or developing next-generation biologics.
References
[1] EvaluatePharma. (2023). World Preview of the Biologics Market.
[2] CDC. (2022). Autoimmune Disease Statistics.
[3] U.S. Food and Drug Administration. (2023). Biosimilar Approval Announcements.
